Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|September 29, 2016
Balancing Cost and Care in Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses challenges balancing the quality of care with the high cost of treatments.
Advertisement
Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses challenges balancing the quality of care with the high cost of treatments.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5